<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286766</url>
  </required_header>
  <id_info>
    <org_study_id>4-2009-0332</org_study_id>
    <nct_id>NCT01286766</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma</brief_title>
  <official_title>A Randomized Phase II Trial of Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Number of patients planned The study adopted two parallel phase II studies, with the same P1&#xD;
      and P0 in each arm, suggested by Logan. The investigators hypothesized a target ORR of&#xD;
      interest, P1=50, and a lower ORR, P0=25 with the treatment of DCS and DCF, respectively.&#xD;
      Under the assumption of α-error=0.05 and β-error= 0.2, using sample size tables of A'Hern, 26&#xD;
      patients were required per arm to achieve the desired statistical power. Finally, taking a&#xD;
      20% drop-out rate into consideration, the overall number of enrolled patients was 62.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment scheme&#xD;
&#xD;
        -  Screening period: D-21 to D1 (treatment day)&#xD;
&#xD;
        -  Preoperative screening includes EUS, laparoscopy (optional), EGD and abd-pelvic CT scan.&#xD;
&#xD;
        -  Preoperative clinical staging is based on the guideline of Japanese Gastric Cancer&#xD;
           Association (JGCA, 1998)&#xD;
&#xD;
        -  Tumor response is assessed every 2 cycles (6 weeks)&#xD;
&#xD;
        -  Treatment is repeated until,.&#xD;
&#xD;
             -  4 cycles&#xD;
&#xD;
             -  progressive disease&#xD;
&#xD;
             -  unacceptable toxicity&#xD;
&#xD;
             -  patient's withdrawal&#xD;
&#xD;
        -  Gastric surgery should be performed within 4~6 weeks of the last dose of chemotherapy&#xD;
&#xD;
        -  Gastric surgery is for curative aim and should include ≥ D2 LN dissection.&#xD;
&#xD;
        -  Patients who received R0 resection should receive at least 4-cycled adjuvant&#xD;
           chemotherapy with 5-FU and cisplatin.&#xD;
&#xD;
        -  Palliative chemotherapy should be indicated for inoperable progressive disease or who&#xD;
           failed curative resection. 5-FU and oxaliplatin combination is recommended as first-line&#xD;
           therapy.&#xD;
&#xD;
        -  Follow up for survival is repeated every 3 months for 2 years&#xD;
&#xD;
      Study period Patient enroll period for 12 months., and follow-up duration for further 12&#xD;
      months., resulting total study period of 24 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RECIST(Response Evaluation Criteria in Solid Tumors)</measure>
    <time_frame>written in the description part below</time_frame>
    <description>safety : every cycle adverse event/serious adversr event evaluation from NCI-CTC(version 3.0)&#xD;
efficacy : tumor response is assessed every 2 cycles (6weeks) -&gt; tumor response assessment(RECIST&lt;Response Evaluation Criteria in Solid Tumor&gt; 1.0 version use)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>DCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DCS: docetaxel with cisplatin with TS-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DCF : docetaxel with cisplatin with 5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCS (docetaxel with cisplatin with TS-1)</intervention_name>
    <description>S-1: 70 mg/m2 #2 bid PO, D1-14&#xD;
Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8&#xD;
Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks.</description>
    <arm_group_label>DCS</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>CDDP</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCF (docetaxel with cisplatin with 5-FU)</intervention_name>
    <description>5-FU: 1,000 mg/m2 CI, D1-3&#xD;
Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by&#xD;
Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.&#xD;
Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)&#xD;
treatment is repeated until 4 cycles</description>
    <arm_group_label>DCF</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Taxotere</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically confirmed gastric adenocarcinoma&#xD;
&#xD;
          -  Age 18 to 70 years old&#xD;
&#xD;
          -  ECOG performance Status 0~1&#xD;
&#xD;
          -  Preoperative clinical staging by Japanese Gastric Cancer Association (JGCA): cT3N2&#xD;
             (IIIB), cT4N0-3 (IIIA~IV), M0, P0, H0, CY0&#xD;
&#xD;
          -  No pretreatment (radiotherapy or chemotherapy) for gastric cancer&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
               -  Hb ≥ 9.0 g/dL&#xD;
&#xD;
               -  WBC ≥ 4,000/µL&#xD;
&#xD;
               -  ANC ≥ 2,000/µL (*ANC = Neutrophil segs ＋ Neutrophil bands)&#xD;
&#xD;
               -  Platelet ≥ 100 × 103/ µL&#xD;
&#xD;
               -  Total bilirubin: ≤ 1.5 × UNL&#xD;
&#xD;
               -  CCr ≥ 60 ml/min (by laboratory or Cockcroft-Gault Formula)&#xD;
&#xD;
               -  AST/ALT, ALP: ≤ 2.5 × UNL&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastasis on diagnosis&#xD;
&#xD;
          -  cT1-2&#xD;
&#xD;
          -  Cancer of gastroesophageal junction (GEJ)&#xD;
&#xD;
          -  Poor oral intake or absorption deficiency syndrome&#xD;
&#xD;
          -  Gastric outlet obstruction, perforation or bleeding&#xD;
&#xD;
          -  Medically uncontrollable chronic illness or infection&#xD;
&#xD;
          -  Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          -  History of clinically significant cardiac disease&#xD;
&#xD;
          -  Past or concurrent history of neoplasm last &lt; 5 year other than gastric cancer&#xD;
&#xD;
          -  Prior gastrectomized patients&#xD;
&#xD;
          -  Concomitant administration of any other experimental drug under investigation&#xD;
&#xD;
          -  Peripheral neuropathy ≥ NCI-CTC grade 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresectable</keyword>
  <keyword>locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

